Peramivir pharmacokinetics in a patient receiving continuous veno-venous hemodiafiltration during the 2009 H1N1 influenza A pandemic.
Identifieur interne : 001939 ( Ncbi/Merge ); précédent : 001938; suivant : 001940Peramivir pharmacokinetics in a patient receiving continuous veno-venous hemodiafiltration during the 2009 H1N1 influenza A pandemic.
Auteurs : Michael L. Bentley ; Alan S. Hollistera ; Amanda C. Hansenb ; Jean A. Smith ; James S. CainSource :
- International journal of clinical pharmacology and therapeutics [ 0946-1965 ] ; 2014.
Descripteurs français
- KwdFr :
- MESH :
- antagonistes et inhibiteurs : Sialidase.
- pharmacocinétique : Antiviraux, Cyclopentanes, Guanidines.
- traitement médicamenteux : Grippe humaine.
- Adulte, Femelle, Humains, Hémodiafiltration, Sous-type H1N1 du virus de la grippe A.
English descriptors
- KwdEn :
- MESH :
- chemical , antagonists & inhibitors : Neuraminidase.
- chemical , pharmacokinetics : Antiviral Agents, Cyclopentanes, Guanidines.
- drug therapy : Influenza, Human.
- Adult, Female, Hemodiafiltration, Humans, Influenza A Virus, H1N1 Subtype.
Abstract
Peramivir is a neuraminidase inhibitor having activity against various influenza A and B subtypes. The main route of elimination is the kidney and a dose reduction is justified for multiple-day therapy when the creatinine clearance is < 50 mL/min. Before the 2009 influenza pandemic, dosing guidelines did not exist for patients receiving continuous renal replacement therapy (CRRT). This case report provides data on the dialysis membrane saturation coefficient (SA) and pharmacokinetic parameters of peramivir in a 29-year-old female receiving continuous veno-venous hemodiafiltration (CVVHDF), a mode of CRRT.
DOI: 10.5414/CP202161
PubMed: 25345428
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000747
- to stream PubMed, to step Curation: 000747
- to stream PubMed, to step Checkpoint: 000765
Links to Exploration step
pubmed:25345428Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Peramivir pharmacokinetics in a patient receiving continuous veno-venous hemodiafiltration during the 2009 H1N1 influenza A pandemic.</title><author><name sortKey="Bentley, Michael L" sort="Bentley, Michael L" uniqKey="Bentley M" first="Michael L" last="Bentley">Michael L. Bentley</name></author><author><name sortKey="Hollistera, Alan S" sort="Hollistera, Alan S" uniqKey="Hollistera A" first="Alan S" last="Hollistera">Alan S. Hollistera</name></author><author><name sortKey="Hansenb, Amanda C" sort="Hansenb, Amanda C" uniqKey="Hansenb A" first="Amanda C" last="Hansenb">Amanda C. Hansenb</name></author><author><name sortKey="Smith, Jean A" sort="Smith, Jean A" uniqKey="Smith J" first="Jean A" last="Smith">Jean A. Smith</name></author><author><name sortKey="Cain, James S" sort="Cain, James S" uniqKey="Cain J" first="James S" last="Cain">James S. Cain</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25345428</idno><idno type="pmid">25345428</idno><idno type="doi">10.5414/CP202161</idno><idno type="wicri:Area/PubMed/Corpus">000747</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000747</idno><idno type="wicri:Area/PubMed/Curation">000747</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000747</idno><idno type="wicri:Area/PubMed/Checkpoint">000765</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000765</idno><idno type="wicri:Area/Ncbi/Merge">001939</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Peramivir pharmacokinetics in a patient receiving continuous veno-venous hemodiafiltration during the 2009 H1N1 influenza A pandemic.</title><author><name sortKey="Bentley, Michael L" sort="Bentley, Michael L" uniqKey="Bentley M" first="Michael L" last="Bentley">Michael L. Bentley</name></author><author><name sortKey="Hollistera, Alan S" sort="Hollistera, Alan S" uniqKey="Hollistera A" first="Alan S" last="Hollistera">Alan S. Hollistera</name></author><author><name sortKey="Hansenb, Amanda C" sort="Hansenb, Amanda C" uniqKey="Hansenb A" first="Amanda C" last="Hansenb">Amanda C. Hansenb</name></author><author><name sortKey="Smith, Jean A" sort="Smith, Jean A" uniqKey="Smith J" first="Jean A" last="Smith">Jean A. Smith</name></author><author><name sortKey="Cain, James S" sort="Cain, James S" uniqKey="Cain J" first="James S" last="Cain">James S. Cain</name></author></analytic><series><title level="j">International journal of clinical pharmacology and therapeutics</title><idno type="ISSN">0946-1965</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antiviral Agents (pharmacokinetics)</term><term>Cyclopentanes (pharmacokinetics)</term><term>Female</term><term>Guanidines (pharmacokinetics)</term><term>Hemodiafiltration</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza, Human (drug therapy)</term><term>Neuraminidase (antagonists & inhibitors)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Antiviraux (pharmacocinétique)</term><term>Cyclopentanes (pharmacocinétique)</term><term>Femelle</term><term>Grippe humaine (traitement médicamenteux)</term><term>Guanidines (pharmacocinétique)</term><term>Humains</term><term>Hémodiafiltration</term><term>Sialidase (antagonistes et inhibiteurs)</term><term>Sous-type H1N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiviral Agents</term><term>Cyclopentanes</term><term>Guanidines</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Antiviraux</term><term>Cyclopentanes</term><term>Guanidines</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Female</term><term>Hemodiafiltration</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Femelle</term><term>Humains</term><term>Hémodiafiltration</term><term>Sous-type H1N1 du virus de la grippe A</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Peramivir is a neuraminidase inhibitor having activity against various influenza A and B subtypes. The main route of elimination is the kidney and a dose reduction is justified for multiple-day therapy when the creatinine clearance is < 50 mL/min. Before the 2009 influenza pandemic, dosing guidelines did not exist for patients receiving continuous renal replacement therapy (CRRT). This case report provides data on the dialysis membrane saturation coefficient (SA) and pharmacokinetic parameters of peramivir in a 29-year-old female receiving continuous veno-venous hemodiafiltration (CVVHDF), a mode of CRRT.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25345428</PMID><DateCompleted><Year>2016</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0946-1965</ISSN><JournalIssue CitedMedium="Print"><Volume>52</Volume><Issue>12</Issue><PubDate><Year>2014</Year><Month>Dec</Month></PubDate></JournalIssue><Title>International journal of clinical pharmacology and therapeutics</Title><ISOAbbreviation>Int J Clin Pharmacol Ther</ISOAbbreviation></Journal><ArticleTitle>Peramivir pharmacokinetics in a patient receiving continuous veno-venous hemodiafiltration during the 2009 H1N1 influenza A pandemic.</ArticleTitle><Pagination><MedlinePgn>1105-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5414/CP202161</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Peramivir is a neuraminidase inhibitor having activity against various influenza A and B subtypes. The main route of elimination is the kidney and a dose reduction is justified for multiple-day therapy when the creatinine clearance is < 50 mL/min. Before the 2009 influenza pandemic, dosing guidelines did not exist for patients receiving continuous renal replacement therapy (CRRT). This case report provides data on the dialysis membrane saturation coefficient (SA) and pharmacokinetic parameters of peramivir in a 29-year-old female receiving continuous veno-venous hemodiafiltration (CVVHDF), a mode of CRRT.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Plasma and effluent samples were collected to calculate the saturation coefficient, plasma half-life, maximum and minimum plasma concentrations, and area under the plasma drug concentration-time curve (AUC) for peramivir. CVVHDF was performed using a Prisma pump and an AN69 filter. During peramivir sampling, the dialysate flow rate was 16.7 mL/min. The mean total ultrafiltrate produced was 14.2 mL/min. To calculate a saturation coefficient (SA), simultaneous sampling of blood and effluent was performed. Pre- and post-filter as well as effluent samples were obtained 4.5 and 8.5 hours following the 3rd dose of 480 mg. Plasma concentrations were also obtained at several time points and the AUC estimated from 0 to 24 hours (AUC0-24).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The maximum plasma concentration (C30min) was 19,477 ng/mL, the minimum plasma concentration (Cmin) 2,750 ng/mL, and AUC0-24 196,166 ng x h/mL. The estimated plasma half-life was 8.2 hours with a log-linear decrease over the 24-hour period suggesting significant extracorporeal clearance. The calculated SA was 0.98, similar to an estimated SA of 1.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Peramivir is readily cleared by CVVHDF having a calculated SA close to 1. The maximum and minimum plasma concentrations, AUC0-24, and plasma half-life was similar to those previously reported. These data will be useful in determining appropriate peramivir dosing regimens for severely ill influenza patients with acute renal impairment managed by CVVHDF.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bentley</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Hollistera</LastName><ForeName>Alan S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Hansenb</LastName><ForeName>Amanda C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Jean A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Cain</LastName><ForeName>James S</ForeName><Initials>JS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Int J Clin Pharmacol Ther</MedlineTA><NlmUniqueID>9423309</NlmUniqueID><ISSNLinking>0946-1965</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003517">Cyclopentanes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006146">Guanidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>QW7Y7ZR15U</RegistryNumber><NameOfSubstance UI="C414210">peramivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003517" MajorTopicYN="N">Cyclopentanes</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006146" MajorTopicYN="N">Guanidines</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017583" MajorTopicYN="Y">Hemodiafiltration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="Y">Influenza A Virus, H1N1 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25345428</ArticleId><ArticleId IdType="pii">12814</ArticleId><ArticleId IdType="doi">10.5414/CP202161</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Bentley, Michael L" sort="Bentley, Michael L" uniqKey="Bentley M" first="Michael L" last="Bentley">Michael L. Bentley</name><name sortKey="Cain, James S" sort="Cain, James S" uniqKey="Cain J" first="James S" last="Cain">James S. Cain</name><name sortKey="Hansenb, Amanda C" sort="Hansenb, Amanda C" uniqKey="Hansenb A" first="Amanda C" last="Hansenb">Amanda C. Hansenb</name><name sortKey="Hollistera, Alan S" sort="Hollistera, Alan S" uniqKey="Hollistera A" first="Alan S" last="Hollistera">Alan S. Hollistera</name><name sortKey="Smith, Jean A" sort="Smith, Jean A" uniqKey="Smith J" first="Jean A" last="Smith">Jean A. Smith</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001939 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001939 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:25345428
|texte= Peramivir pharmacokinetics in a patient receiving continuous veno-venous hemodiafiltration during the 2009 H1N1 influenza A pandemic.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:25345428" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |